Complete the VX-522 Phase 1/2 study and share its data
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 1 Aug 2024
- Due
- 30 Jun 2025
- Checked
- 10 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Vertex expects to complete the trial and share data from this study in the first half of 2025.”
What we found
Evidence strength A What the grades mean
Filings after the June 2025 deadline show VX-522 dosing was paused and only restarting, with data disclosure later moved to second half 2026.
-
A Vertex Pharmaceuticals 10-Q filed 2025-08-05
“The Independent Data Monitoring Committee has completed its review of VX-522, and endorsed restart of the Phase 1/2 clinical trial evaluating VX-522. We expect to resume dosing in the multiple ascending dose portion of this trial in the near term.” ✓ confirmed on the page
-
A Vertex Pharmaceuticals 8-K filed 2026-02-12
“Vertex is targeting completion of dosing in the multiple ascending dose (MAD) portion of the Phase 1/2 study of VX-522 and disclosure of the data in the second half of 2026.” ✓ confirmed on the page
Market reaction: the shares moved -20.6% against the S&P 500 over the three sessions around the disclosure (4 Aug 2025 to 7 Aug 2025). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- VX-522 Phase 1/2 study data
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Vertex Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-VRTX-006542 · Corrections policy